145 related articles for article (PubMed ID: 17336621)
1. Successful treatment of delayed pressure urticaria with anti-TNF-alpha.
Magerl M; Philipp S; Manasterski M; Friedrich M; Maurer M
J Allergy Clin Immunol; 2007 Mar; 119(3):752-4. PubMed ID: 17336621
[No Abstract] [Full Text] [Related]
2. Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha.
John H; Whallett A; Quinlan M
Eye (Lond); 2007 Nov; 21(11):1434-5. PubMed ID: 17693996
[No Abstract] [Full Text] [Related]
3. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept).
Pastor N; Betlloch I; Pascual JC; Blanes M; Bañuls J; Silvestre JF
Clin Exp Dermatol; 2006 Jan; 31(1):152-3. PubMed ID: 16309525
[No Abstract] [Full Text] [Related]
4. Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors.
Wilson LH; Eliason MJ; Leiferman KM; Hull CM; Powell DL
J Am Acad Dermatol; 2011 Jun; 64(6):1221-2. PubMed ID: 21571206
[No Abstract] [Full Text] [Related]
5. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis.
Gualdi G; Monari P; Rossi MT; Crotti S; Calzavara-Pinton PG
Br J Dermatol; 2012 Jun; 166(6):1373-4. PubMed ID: 22212112
[No Abstract] [Full Text] [Related]
6. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy.
Cassano N; Coviello C; Loconsole F; Miracapillo A; Vena GA
Eur J Dermatol; 2006; 16(3):316-7. PubMed ID: 16709508
[No Abstract] [Full Text] [Related]
7. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept.
Prey S; Robert PY; Drouet M; Sparsa A; Roux C; Bonnetblanc JM; Bédane C
Acta Derm Venereol; 2007; 87(1):74-5. PubMed ID: 17225020
[No Abstract] [Full Text] [Related]
8. Successful use of infliximab following a failed course of etanercept in a pediatric patient.
Farnsworth NN; George SJ; Hsu S
Dermatol Online J; 2005 Dec; 11(3):11. PubMed ID: 16409907
[No Abstract] [Full Text] [Related]
9. Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?
Salvarani C; Pipitone N; Boiardi L; Hunder GG
Ann Rheum Dis; 2008 May; 67(5):577-9. PubMed ID: 18408108
[No Abstract] [Full Text] [Related]
10. Adolescent plaque psoriasis: our experience using etanercept.
Ruiz-Villaverde R; Sánchez-Cano D; Abalos-Medina G
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):976-7. PubMed ID: 19207668
[No Abstract] [Full Text] [Related]
11. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
Khanna D; McMahon M; Furst DE
Arthritis Rheum; 2004 Apr; 50(4):1040-50. PubMed ID: 15077286
[No Abstract] [Full Text] [Related]
12. Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha.
Fitch PG; Cron RQ
J Rheumatol; 2006 Apr; 33(4):825; author reply 826-7. PubMed ID: 16583487
[No Abstract] [Full Text] [Related]
13. QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy.
Desai N; Raste Y; Cooke NT; Harland CC
Br J Dermatol; 2008 May; 158(5):1137-8. PubMed ID: 18279462
[No Abstract] [Full Text] [Related]
14. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis.
Spadaro A; Ceccarelli F; Scrivo R; Valesini G
Ann Rheum Dis; 2008 Nov; 67(11):1650-1. PubMed ID: 18854519
[No Abstract] [Full Text] [Related]
15. Successful treatment of Langerhans'-cell histiocytosis with etanercept.
Henter JI; Karlén J; Calming U; Bernstrand C; Andersson U; Fadeel B
N Engl J Med; 2001 Nov; 345(21):1577-8. PubMed ID: 11794238
[No Abstract] [Full Text] [Related]
16. [New concept in chronic heart failure. Blocking the function of tumor necrosis factor].
MMW Fortschr Med; 2000 Mar; 142(13):51. PubMed ID: 10783628
[No Abstract] [Full Text] [Related]
17. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.
Antoniou C; Dessinioti C; Stratigos A; Avgerinou G; Stavropoulos P; Katsambas A
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):979-82. PubMed ID: 19470056
[No Abstract] [Full Text] [Related]
18. Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept.
Litton G
Am J Hematol; 2008 Apr; 83(4):344. PubMed ID: 18186526
[No Abstract] [Full Text] [Related]
19. The role of the QuantiFERON-TB Gold test as screening prior to administration of tumor necrosis factor inhibitors.
Martinez LC; Harrison-Balestra C; Caeiro JP; Nousari CH
Arch Dermatol; 2007 Jun; 143(6):809-10. PubMed ID: 17576961
[No Abstract] [Full Text] [Related]
20. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.
Molloy ES; Langford CA; Clark TM; Gota CE; Hoffman GS
Ann Rheum Dis; 2008 Nov; 67(11):1567-9. PubMed ID: 18677012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
